Sustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticles

Chemical Engineering Science

Volumn 125, Issue , 2015, Pages 98-107

  Carrillo Conde, Brenda R ^a   Darling, Ross J ^b   Seiler, Steven J ^a   Ramer Tait, Amanda E ^b,c   Wannemuehler, Michael J ^b   Narasimhan, Balaji ^a  

^a Iowa State University of Science and Technology   (United States)

^b IOWA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Delivery; Nanoparticles; Polyanhydrides; Stability; Therapeutic antibodies

Indexed keywords

BIOACTIVITY; BODY FLUIDS; CONVERGENCE OF NUMERICAL METHODS; DISEASES; MONOCLONAL ANTIBODIES; NANOPARTICLES; SURFACE PLASMON RESONANCE; SYNTHESIS (CHEMICAL);

BIOLOGICALLY ACTIVE PROTEINS; CHEMICAL INSTABILITY; CHRONIC INFLAMMATION; DELIVERY; HUMAN CYTOMEGALOVIRUS; MACULAR DEGENERATION; POLYANHYDRIDES; THERAPEUTIC ANTIBODIES;

ANTIBODIES;

EID: 85027926563     PISSN: 00092509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ces.2014.08.015     Document Type: Article

References (47)

1. Blake P.A., Feldman R.A., Buchanan T.M., Brooks G.F., Bennett J.V. Serologic therapy of tetanus in the United States. J. Am. Med. Assoc. 1976, 42:42-44.
2. Carrillo-Conde B., Schiltz E., Torres M.P., Yu J., Phillips G., Minion C., Wannemuehler M.J., Narasimhan B. Amphipilic polyanhydrides for stabilization of Yersinia pestis antigens. Acta Biomater. 2010, 6:3110-3119.
3. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin. Immunol. 1999, 93:5-15.
4. Casadevall A., Dadachova E., Pirofski L. Passive antibody therapy for infectious diseases. Nat. Rev. 2004, 2:695-703.
5. Cathou R.E., Kulczycki A., Haber E. Structural features of y-immunoglobulin, antibody, and their fragments: circular dichroism studies. Biochemistry 1968, 17:3958-3964.
6. Conix A. Poly[1,3-bis(p-carboxyphenoxy)-propane anhydride]. Macromol. Synth. 1966, 2:95-98.
7. Determan A., Graham J.R., Pfeiffer K.A., Narasimhan B. The role of microsphere fabrication methods on the stability and release kinetics of ovalbumin encapsulated in polyanhydride microspheres. J. Microencapsul. 2006, 23:832-843.
8. Determan A.S., Trewyn B.G., Lin V.S.Y., Nilsen-Hamilton M., Narasimhan B. Encapsulation, stabilization, and release of BSA-FITC from polyanhydride microspheres. J. Control Release 2004, 100:97-109.
9. Determan A.S., Wilson J.H., Kipper M.J., Wannemuehler M.J., Narasimhan B. Protein stability in the presence of polymer degradation products: Consequences for controlled release formulations. Biomaterials 2006, 27:3312-3320.
10. Dooley H., Grant S.D., Harris W.J., Porter A.J. Stabilization of antibody fragments in adverse environments. Biotechnol. Appl. Biochem. 1998, 28:77-83.
11. Grainger D.W. Controlled-release and local delivery of therapeutic antibodies. Expert Opin. Biol. Ther. 2004, 4:1029-1044.
12. Guziewicz N., Best A., Perez-Ramirez B., Kaplan D.L. Lyophilized silk fibroin hydrogels for the sustained local delivery of therapeutic monoclonal antibodies. Biomaterials 2011, 32:2642-2650.
13. Hahn J. Biopharmaceuticals - challenges and opportunities facing the drug-delivery industry. Touch Briefings 2009, 114-118.
14. Haughney S.L., Petersen L.K., Schoofs A.D., Ramer-Tait A.E., King J.D., Briles D.E., Wannemuehler M.J., Narasimhan B. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. Acta Biomater. 2013, 9:8262-8271.
15. Havell E.A., Rogerson B.J. Endotoxin-induced tumor necrosis factor alpha synthesis in murine embryo fibroblasts. Infect. Immun. 1993, 65:1630-1635.
16. Huntimer L., Ramer-Tait A.E., Petersen L.K., Ross K.A., Walz K.A., Wang C., Hostetter J., Narasimhan B., Wannemuehler M.J. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery. Adv. Healthcare Mater. 2013, 2:369-378.
17. Kipper M.J., Shen E., Determan A.S., Narasimhan B. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery. Biomaterials 2002, 23:4405-4412.
18. Kipper M.J., Wilson J.H., Wannemuehler M.J., Narasimhan B. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J. Biomed. Mater. Res. A 2006, 76:798-810.
19. Lang A.B., Cryz S.J., Schurch U., Ganss M.T., Bruderer U. Immunotherapy with monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J. Immunol. 1993, 151:466-472.
20. Lopac S.K., Torres M.P., Wilson-Welder J.H., Wannemuehler M.J., Narasimhan B. Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheres. J. Biomed. Mater. Res. B 2009, 91:938-947.
21. Mold D.R., Sweeney K.R. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development. Curr. Opin. Drug Discov. Dev. 2007, 10:84-96.
22. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010, 9:767-774.
23. O'Connell M.A., Kelleher D., Liskamp R.M., Hall N., O'Neill L.A.J., Long A. TNF-mediated cytotoxicity of L929 cells: role of staurosporine in enchancement of cytotoxicity and translocation of protein kinase C isozymes. Cytokine 1997, 9:83-92.
24. Petersen L.K., Phanse Y., Ramer-Tait A.E., Wannemuehler M.J., Narasimhan B. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. Mol. Pharm. 2012, 9:874-882.
25. Petersen L.K., Sackett C.K., Narasimhan B. High-throughput analysis of protein stability in polyanhydride nanoparticles. Acta Biomater. 2010, 6:3873-3881.
26. Petersen L.K., Xue L., Wannemuehler M.J., Rajan K., Narasimhan B. The simultaneous effect of polymer chemistry and device geometry on the in vitro activation of murine dendritic cells. Biomaterials 2009, 30:5131-5142.
27. Piggee C. Therapeutic antibodies coming through the pipeline. Anal. Chem. 2008, 80:2305-2310.
28. Presta L.G. Engineering antibodies for therapy. Curr. Pharm. Biotechnol. 2002, 3:237-256.
29. Ross, K.A., Loyd, H., Wu, W., Huntimer, L., Wannemuehler, M.J., Carpenter, S., Narasimhan, B., 2014. Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles. J. Biomed. Mater. Res. A.
30. Rouet R., Lowe D., Christ D. Stability engineering of the human antibody repertoire. FEBS Lett. 2014, 588:269-277.
31. Saltzman W.M. Antibodies for treating and preventing disease: the potential role of polymeric controlled release. Crit. Rev. Ther. Drug Carrier Sys. 1993, 10:111-142.
32. Salzman W.M., Sheppard N.F., Mchugh M.A. Controlled antibody release from matrix of poly(ethylene-co-vinyl acetate) fractionated with a supercritical fluid. J. Appl. Polym. Sci. 1993, 48:1493-1500.
33. Scweizer D., Schonhammer K., Jahn M., Gopferich A. Protein-polyanion interactions for the controlled release of monoclonal antibodies. Biomacromolecules 2013, 14.
34. Shen E., Kipper M.J., Dziadul B., Lim M.K., Narasimhan B. Mechanistic relationships between polymer microstructure and drug release kinetics in bioerodible polyanhydrides. J. Control Release 2002, 82:115-125.
35. Shen E., Pizsczek R., Dziadul B., Narasimhan B. Microphase separation in bioerodible copolymers for drug delivery. Biomaterials 2001, 22:201-210.
36. Sheoran A.S., Lunn D.P., Holmes M.A. Monoclonal antibodies to subclass-specific antigenic determinants on equine immunoglobulin gamma chains and their characterization. Vet. Immunol. Immunopathol. 1998, 62:153-165.
37. Torres M.P., Determan A.S., Anderson G.L., Mallapragada S.K., Narasimhan B. Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 2007, 28:108-116.
38. Torres M.P., Vogel B.M., Narasimhan B., Mallapragada S.K. Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms. J. Biomed. Mater. Res. A 2006, 76:102-110.
39. Torres M.P., Wilson-Welder J.H., Lopac S.K., Phanse Y., Carrillo-Conde B., Ramer-Tait A.E., et al. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater. 2011, 11:2857-2864.
40. Tsukamoto H., Fukudome K., Kohara J., Nakatake H., Kimoto M. Preparation of recombinant murine tumor necrosis factor-α in Escherichia coli: a rapid method to remove tags from fusion proteins by thrombin-cleavage and ion-exchange chromatography. Protein Expr. Purif. 2007, 56:138-144.
41. Ulery B.D., Kumar D., Ramer-Tait A.E., Metzger D.W., Wannemuehler M.J., Narasimhan B. Design of a protective single-dose intransal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 2011, 6:e17642. (doi:17610.11371/journal.pone.0017642).
42. Ulery B.D., Petersen L.K., Phanse Y., Kong C.S., Broderick S.R., Kumar D., Ramer-Tait A.E., Carrillo-Conde B., Rajan K., Wannemuehler M.J., Bellaire B.H., Metzger D.W., Narasimhan B. Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci. Rep. 2011, 1:198. 10.1038/srep00198.
43. Ulery B.D., Phanse Y., Sinha A., Wannemuehler M.J., Narasimhan B., Bellaire B.H. Polymer chemistry influences monocytic uptake of polyanhydride nanospheres. Pharm. Res. 2009, 26:683-690.
44. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 1999, 185:129-188.
45. Wang W., Singh S., Zeng D.L., King K., Nema S. Antibody structure, instability, and formulation. J. Pharm. Sci. 2007, 96:1-26.
46. Zemser M., Friedman M., Katzhendler J., Greene L., Minsky A., Gorinstein S. Relationship between functional properties and structure of ovalbumin. J. Protein Chem. 1994, 13:261-274.
47. Zhu G., Mallery S.R., Schwendeman S.P. Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide). Nat. Biotechnol. 2000, 18:52-57.